Harmony Biosciences Holdings Inc HRMY

NAS: HRMY | ISIN: US4131971040   3/05/2024
31,57 USD (-0,38%)
(-0,38%)   3/05/2024

30 april 2024 · Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets · Persbericht

16 april 2024 · Harmony Biosciences To Report First Quarter 2024 Financial Results On April 30, 2024 · Persbericht

11 april 2024 · Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist · Persbericht

3 april 2024 · Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) Of Pitolisant In Patients With Prader-Willi Syndrome · Persbericht

26 maart 2024 · Harmony Biosciences To Participate In 23Rd Annual Needham Virtual Healthcare Conference · Persbericht

28 februari 2024 · Harmony Biosciences To Participate In Upcoming Investor Conferences · Persbericht

21 februari 2024 · U.s. Food And Drug Administration Grants Priority Review To Harmony Biosciences' Application For Wakix® (Pitolisant) In Pediatric Narcolepsy · Persbericht

20 februari 2024 · Harmony Biosciences Receives U.s. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome · Persbericht

8 februari 2024 · Harmony Biosciences To Report Fourth Quarter And Full Year 2023 Financial Results On February 22, 2024 · Persbericht

8 januari 2024 · Harmony Biosciences Preliminary Unaudited Fourth Quarter And Full Year 2023 Net Product Revenue Increases More Than 30 Percent; Provides 2024 Net Product Revenue Guidance · Persbericht

3 januari 2024 · Harmony Biosciences To Present At The 42Nd Annual J.p. Morgan Healthcare Conference · Persbericht

7 december 2023 · Harmony Biosciences Announces Positive Topline Data From Phase 2 Signal Detection Study Evaluating Pitolisant In Adult Patients With Myotonic Dystrophy Type 1 · Persbericht

5 december 2023 · Harmony Biosciences To Present Results From Behavioral Study In 22Q11.2 Deletion Syndrome At American College Of Neuropsychopharmacology Annual Meeting · Persbericht

8 november 2023 · Harmony Biosciences Appoints Peter Anastasiou To Its Board Of Directors · Persbericht

26 oktober 2023 · Harmony Biosciences Showcases The Newest Patients At The Heart And Progress At The Heart Award Recipients · Persbericht

17 oktober 2023 · Harmony Biosciences To Report Third Quarter 2023 Financial Results On October 31, 2023 · Persbericht

13 oktober 2023 · Harmony Biosciences Announces Topline Data From Phase 3 Intune Study Evaluating Pitolisant In Patients With Idiopathic Hypersomnia · Persbericht

11 oktober 2023 · Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals And Expands Pipeline · Persbericht

5 oktober 2023 · Harmony Biosciences Presents New Secondary Outcome Data From Phase 2 Signal Detection Study In Patients With Prader-Willi Syndrome · Persbericht

27 september 2023 · Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc. · Persbericht

Mijn selecties